La cadena de opciones muestra datos clave de las opciones de acciones de Outlook Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Outlook Therapeutics..

Outlook Therapeutics (NASDAQ:OTLK) Bolsa, Cadena de Opciones

Outlook Therapeutics

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Descubre qué acciones sobrevendidas del sector salud tienen un RSI por debajo de 30 y podrían estar infravaloradas.

3 acciones estadounidenses de atención médica que podrían despegar este mes

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics Inc

Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) reported quarterly earnings of $0.92 per share which missed the analyst consensus estimate of $0.98 by 6.12 percent. This is a 6.98 percent increase over earnings of $0.86 per share from the same period last year. The company reported quarterly sales of $948.50 million which missed the analyst consensus estimate of $1.02 billion by 7.26 percent. This is a 5.81 percent increase over sales of $896.40 million the same period last year.

Earnings

Earnings Misses

Carlyle Group Q4 2024 Adj EPS $0.92 Misses $0.98 Estimate, Sales $948.50M Miss $1.02B Estimate

Deploying a Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) supercharger stall in the U.S. costs between $40,000 to $45,000, or roughly the price of the company&#8217;s Model 3 base version, according to Tesla executive Max de Zegher.
What Happened: While the cost for deploying a stall is now between $40,000 to $45,000, the company expects to deploy the new version of its supercharger called V4 with V4 cabinet for less than $40,000 per stall, de Zegher, Director of Charging for North America, Europe Middle East &amp; Africa as well as the Asia Pacific, said. The first V4 superchargers with V4 cabinets will be deployed in the third quarter of 2024, he added. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">$40k-$45k/stall
&mdash; Max de Zegher (@MdeZegher) <a href="https://twitter.com/MdeZegher/status/1889169141107704038?ref_src=twsrc%5Etfw">February 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Tesla launched its V4 posts last year using a V3 cabinet, thereby limiting power output. The company is now eyeing deploying V4 posts with V4 cabinets to ensure maximum performance. 
The V4 Cabinet, Tesla previously said, supports 400V-1000V vehicle architectures and is capable of delivering up to 500kW for cars. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f44d;&#x1f3fc; Engineering is working weekends on it, aiming for first pilot sites in Q3. Despite increased capability of up to 500kW/stall, we should be able to deploy it for less than $40k/stall. I expect <a href="https://twitter.com/itskyleconner?ref_src=twsrc%5Etfw">@itskyleconner</a> to be one of the first ones to plug in!
&mdash; Max de Zegher (@MdeZegher) <a href="https://twitter.com/MdeZegher/status/1889172565425615117?ref_src=twsrc%5Etfw">February 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: In 2024, Tesla opened <a href="https://www.benzinga.com/25/01/42760189/tesla-says-it-added-11000-superchargers-in-2024">over 11,000 supercharger stalls</a>, taking the total number of superchargers globally to over 65,000.
Estimating that Tesla spent $45,000 on each of these stalls, the company spent $495 million on deploying superchargers in the year, in line with Musk&#8217;s word of investing $500 million through the end of 2024 to expand the charging network. 
With Tesla itself adding more EVs on the road and opening the supercharging network to EV drivers from rival automakers including Ford and Rivian in North America, demand for charging infrastructure is on a steady rise.
Earlier this month, de Zegher said that the company is working to keep up with demand and is looking to add 500-1000 supercharger stalls <a href="https://www.benzinga.com/tech/25/02/43554984/mercedes-benz-gains-access-to-tesla-supercharger-network-looking-to-add-500-1000-supercharger-stalls-a-month-in-north-america-says-ev-giants-exec">each month in North America alone. </a>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43588718/lucid-ceo-envisions-ev-maker-licensing-tech-more-than-building-cars" target="_blank" rel="noreferrer noopener">Peter Rawlinson Wants Lucid To Be The Intel Of EVs: ‘You Flash Your Microsoft Office… Bill Gates Gets His Royalty… I Want To Be Like That&#8217;</a></li>
</ul>
Photo courtesy: Tesla

Tech

TSLA

Deploying Tesla Superchargers Cost $40,000-$45,000 Per Stall Or Roughly The Price Of Model 3 Sedan, Says Exec

WIIM

DuPont shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 outlook.

Guidance

SQNS

Sequans Expects Q1 2025 Licensing Revenue Related To Qualcomm Deal To Be Lower Sequentially

Econ #s

NFIB Small Business Optimism (Jan) 102.8 vs 104.6 Est; 105.1 Prior

Sequans Expects Q1 Total Revenue Of $7M - $8M, Est $6.50M

General

Solidion's Silane-Free Silicon Anode Patents For High Energy Lithium-ion Batteries

MYT Netherlands Parent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NYSE">MYTE</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.06 by 116.67 percent. This is a 225 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $238.00 million which beat the analyst consensus estimate of $217.77 million by 9.29 percent. This is a 12.22 percent increase over sales of $212.08 million the same period last year.

MYTE

MYT Netherlands Parent Q2 Adj $0.13 Beats $0.06 Estimate, Sales $238.00M Beat $217.77M Estimate

Evercore ISI Group analyst Samir Khanal upgrades Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) from In-Line to Outperform and maintains the price target from $31 to $31.

Upgrades

Price Target

Analyst Ratings

Evercore ISI Group Upgrades Brixmor Property Group to Outperform, Maintains Price Target to $31

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3" rowspan="1">2025 Financial Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Dollars in millions, unless noted</td>
<td colspan="1" rowspan="1">1Q'25E</td>
<td colspan="1" rowspan="1">Full Year 2025E</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales</td>
<td colspan="1" rowspan="1">~$3,025</td>
<td colspan="1" rowspan="1">$12,800 - $12,900</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating EBITDA(2)</td>
<td colspan="1" rowspan="1">~$760</td>
<td colspan="1" rowspan="1">$3,325 - $3,375</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS(2)</td>
<td colspan="1" rowspan="1">~$0.95</td>
<td colspan="1" rowspan="1">$4.30 - $4.40</td>
</tr>
</tbody>
</table>
</figure>

DuPont FY2025 Outlook: Adj EPS $4.30-$4.40 vs $4.34 Est; Sales $12.800B-$12.900B vs $12.92B Est

Leidos is initiating fiscal year 2025 guidance as specified in the table below.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Measure</td>
<td colspan="1" rowspan="1">FY25 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues (billions)</td>
<td colspan="1" rowspan="1">$16.9 - $17.3</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin</td>
<td colspan="1" rowspan="1">Mid-High 12%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Diluted EPS</td>
<td colspan="1" rowspan="1">$10.35 - $10.75</td>
</tr>
</tbody>
</table>
</figure>

LDOS

Leidos Holdings Expects FY25 Revenue Of $16.9B-$17.3B Vs $16.98B Est, Adj EPS Of $10.35-$10.75 Vs $10.58 Est

DuPont Sees Q1 Adj EPS $0.95 vs $0.94 Est; Sees Sales $3.025B vs $3.05B Est

Nano Labs' AI Inference Device, YangTuo LLM Workstation Completes The Deployment Of DeepSeek.

Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. The company reported quarterly sales of $10.98 million which beat the analyst consensus estimate of $10.50 million by 4.57 percent. This is a 130.04 percent increase over sales of $4.77 million the same period last year.

Earnings Beats

Sequans Communications Q4 2024 Adj EPADS $(0.08) Misses $(0.07) Estimate, Sales $10.98M Beat $10.50M Estimate

OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) reported quarterly sales of $66.81 million which beat the analyst consensus estimate of $65.39 million by 2.17 percent. This is a 18.72 percent increase over sales of $56.27 million the same period last year.

OrganiGram Holdings Q1 2025 Sales C$66.81M Beat C$65.39M Estimate, Net Loss Of C$22.96M Vs. C$15.75M YoY

WESCO Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) reported quarterly adjusted earnings of $3.16 per share which missed the analyst consensus estimate of $3.23 by 2.17 percent. This is a 19.25 percent increase over earnings of $2.65 per share from the same period last year. The company reported quarterly sales of $5.50 billion which beat the analyst consensus estimate of $5.41 billion by 1.68 percent. This is a 0.48 percent increase over sales of $5.47 billion the same period last year.

WESCO Intl Q4 Adj $3.16 Misses $3.23 Estimate, Sales $5.50B Beat $5.41B Estimate

DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $0.98 by 15.31 percent. This is a 29.89 percent increase over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $3.092 billion which beat the analyst consensus estimate of $3.068 billion by 0.80 percent. This is a 6.69 percent increase over sales of $2.898 billion the same period last year.

DuPont Q4 2024 Adj. EPS $1.13 Beats $0.98 Estimate, Sales $3.092B Beat $3.068B Estimate

ADEA

Adeia Renews Multi-Year Intellectual Property  License Agreement With Australia's Fetch TV

Leidos Holdings Q4 2024 Adj. EPS $2.37 Beats $2.27 Estimate, Sales $4.365B Beat $4.134B Estimate

BYDDY

HSAI

Hesai And BYD Partner To Provide Automotive Lidar For More Than 10 BYD Models

Outlook Therapeutics ( ($OTLK) ) has released its Q4 earnings. Here is a breakdown of the information Outlook Therapeutics presented to its investo...

Outlook Therapeutics Reports 2024 Financial Results

Outlook Therapeutics (OTLK) has disclosed a new risk, in the Supply Chain category. Outlook Therapeutics faces significant business risk due to its...

Outlook Therapeutics Faces Business Risks from Third-Party Manufacturing Dependencies

Outlook Therapeutics (OTLK) has completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT, the second of two clini...

Outlook Therapeutics' ONS-5010 shown to be non-inferior to Lucentis in wet AMD

Outlook falls 10% on ONS-5010 update, warrant inducements

Outlook Therapeutics (OTLK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao fr...

Positive Outlook for Outlook Therapeutics Driven by Promising ONS-5010 Data and Strategic Market Positioning

Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target of $...

Chardan Capital Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)

Outlook Therapeutics (OTLK) announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting being held January 18-2...

Outlook Therapeutics announces presentation of data from NORSE EIGHT

Outlook Therapeutics (OTLK) announced Faisal Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Sukhtian wil...

Outlook Therapeutics appoints Sukhtian as Chairman of the board of directors

Outlook Therapeutics names Faisal Sukhtian as chair

Outlook Therapeutics ( ($OTLK) ) has provided an update. On January 31, 2025, Outlook Therapeutics entered into a Securities Purchase Agreement wit...

Outlook Therapeutics Secures Funding and Board Restructures

RHHBY

Management

Press Releases

Outlook Therapeutics® Announces Executive Leadership Transition

Health Care

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Streamlines Operations

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® Participates in Virtual Investor "What This Means" Segment

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Comments

Outlook Therapeutics

Outlook Therapeutics (OTLK) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL